Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Ultragenyx Pharmaceutical (RARE) Ownership Overview
3.93% Insiders
29.90% Mutual Funds
35.75% Other Institutional Investors
13.81% ETFs
16.60% Public Companies and Individual Investors
The ownership structure of Ultragenyx Pharmaceutical (RARE) stock is a mix of institutional, retail, and individual investors. Approximately 79.47% of the company’s stock is owned by Institutional Investors, 3.93% is owned by Insiders, and 16.60% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | Emil Kakkis President & Ceo,director | xxxxxxxxxxxxx | $495231 |
| Dec 11, 2024 | Emil Kakkis President & Ceo,director | xxxxxxxxxxxxx | $413650 |
| Oct 11, 2024 | Howard Horn Cfo | xxxxxxxxxxxxx | $393853 |
| Sep 05, 2024 | Emil Kakkis President & Ceo,director | xxxxxxxxxxxxx | $1117000 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $11156501 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 8,123,722 | Institution | 8.80% | 345,176,948 | |
| 7,591,736 | Institution | 8.22% | 322,572,863 | |
| 4,298,003 | Institution | 4.65% | 182,622,147 | |
| 2,748,590 | Insider | 2.98% | 116,787,589 | |
| 2,190,924 | Institution | 2.37% | 93,092,361 | |
| 2,082,400 | Institution | 2.26% | 88,481,176 | |
| 1,977,526 | Institution | 2.14% | 84,025,080 | |
| 1,655,837 | Institution | 1.79% | 70,356,514 | |
| 1,576,114 | Institution | 1.71% | 66,969,084 | |
| 1,368,385 | Institution | 1.48% | 58,142,679 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 7,591,736 | Institution | 8.22% | 322,572,863 | |
| 2,082,400 | Institution | 2.26% | 88,481,176 | |
| 1,977,526 | Institution | 2.14% | 84,025,080 | |
| 1,655,837 | Institution | 1.79% | 70,356,514 | |
| 1,368,385 | Institution | 1.48% | 58,142,679 | |
| 1,017,798 | Institution | 1.10% | 43,246,237 | |
| 1,010,592 | Institution | 1.09% | 42,940,054 | |
| 974,312 | Institution | 1.06% | 41,398,517 | |
| 921,427 | Institution | 1.00% | 39,151,433 | |
| 861,110 | Institution | 0.93% | 36,588,564 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,759,909 | Institution | 2.99% | 116,109,372 | |
| 2,233,994 | Institution | 2.42% | 93,984,128 | |
| 1,393,769 | Institution | 1.51% | 58,635,862 | |
| 1,267,798 | Institution | 1.37% | 53,336,262 | |
| 1,088,133 | Institution | 1.18% | 47,355,548 | |
| 520,329 | Institution | 0.56% | 22,108,779 | |
| 520,054 | Institution | 0.56% | 22,097,094 | |
| 444,283 | Institution | 0.48% | 19,335,196 | |
| 319,681 | Institution | 0.35% | 13,583,246 | |
| 294,872 | Institution | 0.32% | 12,529,111 |
FAQ
Who Owns Ultragenyx Pharmaceutical (RARE)?
According to the latest TipRanks data, approximately 35.75% of the company's stock is held by institutional investors, 3.93% is held by insiders, and 16.60% is held by retail investors.
What percentage of Ultragenyx Pharmaceutical (RARE) stock is held by institutional investors?
According to the latest TipRanks data, approximately 35.75% of Ultragenyx Pharmaceutical (RARE) stock is held by institutional investors.
What percentage of Ultragenyx Pharmaceutical (RARE) stock is held by retail investors?
According to the latest TipRanks data, approximately 16.60% of Ultragenyx Pharmaceutical (RARE) stock is held by retail investors.
Who owns the most shares of Ultragenyx Pharmaceutical (RARE)?
Vanguard owns the most shares of Ultragenyx Pharmaceutical (RARE).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.